Rapport Navigates Rough IPO Market With Well-Received Offering
Rough Waters For Most That Have Gone Public In 2023
Rapport Therapeutics launched an initial public offering in the middle of a proposed price range, and the CNS-focused company closed slightly above its IPO price on its first day of trading.
